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Summary
Gene expression profiling has the potential to enhance current methods for
the diagnosis of haematological malignancies. Here, we present data on 204
analyses from an international standardization programme that was
conducted in 11 laboratories as a prephase to the Microarray Innovations
in LEukemia (MILE) study. Each laboratory prepared two cell line samples,
together with three replicate leukaemia patient lysates in two distinct stages:
(i) a 5-d course of protocol training, and (ii) independent proficiency testing.
Unsupervised, supervised, and r2 correlation analyses demonstrated that
microarray analysis can be performed with remarkably high intra-laboratory
reproducibility and with comparable quality and reliability.
Keywords: microarray, gene expression profiling, leukaemia, standardiza-
tion, diagnostics.
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Several microarray studies have already demonstrated the
identification of differentially expressed genes associated with
distinct clinical and therapeutically relevant classes of leukae-
mias (Golub et al, 1999; Armstrong et al, 2002; Schoch et al,
2002; Yeoh et al, 2002). Given that microarray assays analyse
the expression of multiple genes in parallel, they appear to be
a robust test method for diagnostic usage (Kohlmann et al,
2003, 2005; Haferlach et al, 2005). However, to date, all of
these studies aimed at subclassifying leukaemia subtypes
through gene expression profiling have been performed
mainly as monocentric studies that included only a limited
number of patients or using mostly RNA specimens that
were predominantly analysed retrospectively from archived
samples.
Here we report data from an international study group
formed around the European Leukemia Network (ELN, http://
www.leukemia-net.org) in 11 laboratories: seven from the
ELN, three from the United States, and one in Singapore. The
so-called Microarray Innovations in LEukemia (MILE) study
programme will prospectively assess the clinical accuracy of
gene expression profiles of 16 acute and chronic leukaemia
subclasses, of myelodysplastic syndromes (MDS), and a ‘‘none
of the target classes’’ control group, as compared to current
routine diagnostic workup in over 3000 patients. As a first step
representing a major effort to standardize the microarray
analysis workflow in the participating centres, a prephase of
the MILE study was performed. This report presents the results
of the prephase, i.e., a standardization programme of the
microarray procedure in the participating laboratories in order
to ensure a robust gene expression profiling test performance
before patient samples were analysed.
Materials and methods
There were two stages in the MILE prephase study: protocol
training and proficiency testing. As part of the initial protocol
training each participating laboratory was provided with
identical equipment, including reagent kits, enzymes, spectro-
photometer, and heat block instruments, and eight microarray
experiments were performed at each centre with an on-site
trainer in the respective laboratory being trained. The eight
samples analysed during the training course were represented
by MCF-7 (breast adenocarcinoma) and HepG2 (liver carci-
noma) cell line total RNA (Ambion, Austin, TX, USA) with
1Æ0 lg and 5Æ0 lg input of total RNA, respectively, and four
leukaemia patient sample lysates prepared from mononuclear
cells obtained after Ficoll density purification. Patient lysates
comprised cells of one chronic myeloid leukaemia (CML), one
chronic lymphocytic leukaemia (CLL), and two replicate
lysates of an AML patient sample (containing a translocation
t(8;21), French-American-British (FAB) type M2). The total
RNA from the patient lysates was extracted at each centre as
part of the training programme, making these samples a test of
the entire microarray process workflow post sample acquisi-
tion (RNeasy kit, Qiagen, Hilden, Germany). Subsequently,
after the training phase and for operator proficiency testing,
each laboratory independently performed four microarray
experiments each for MCF-7 and HepG2 cell lines with inputs
of 1Æ5 lg, 3Æ0 lg, 5Æ0 lg, and 8Æ0 lg total RNA. In total,
204 microarray profiles were included in the analysis (for
details see Appendix SI and SII). The three anonymous
replicate patient lysates were provided by the Laboratory for
Leukaemia Diagnostics in Munich, Germany. All patients
gave their informed consent for participation after having
been advised of the purpose and investigational nature of
the study. The study design adhered to the tenets of the
Declaration of Helsinki and was approved by the ethics
committees of the participating institutions before its initia-
tion. Details on the microarray analysis workflow, image
analysis, quality reports, as well as statistical methods are given
in Appendix SI.
Results
Intra-laboratory reproducibility of gene expression
analyses
As shown in an unsupervised Principal Component Analysis
(PCA), the individual gene expression profiles grouped closely
together with their corresponding biological sample types
based on the underlying similarity, but not according to the
centre where the microarray experiments were performed
(Fig 1). The arrows in Fig 1 indicate that the four leukaemia
sample preparations from Centre 9 (N17-20), as well as one
HepG2 preparation from Centre 3 (N18) were outliers in the
PCA. Large differences in gene expression profiles were also
observed with respect to the manufacturing batches for MCF-7
total RNA, but overall, a high level of reproducibility between
laboratories was seen when a standardized protocol for
microarray analysis was followed by trained operators.
According to the unsupervised PCA plots, replicated gene
expression profiles of the HepG2 cell line were more biolog-
ically homogeneous and not as influenced by manufacturing
batch numbers, as seen for MCF-7 cell line replicates.
Therefore, replicated profiles of the HepG2 cell line were
chosen to further investigate the intra- and inter-laboratory
correlations. All centres generated highly reproducible gene
expression profiles for this cell line, as shown in the box plot
analysis of r2 values from all pairwise comparisons within
each centre for the sample type HepG2 (Fig 2A), where mean
r2 values range from 0Æ973 to 0Æ988. The slightly higher
variability at Centre 11 might be explained by a higher number
of operators and replicate analyses than in other centres.
Figure 2B shows the intra-site repeatability of microarray data
based on quantitative signal values and qualitative detection
calls. The number of generally detected genes for each sample
type at each centre varied from 24 627–27 075 for HepG2 and
25 841–28 953 for MCF-7. The coefficient of variation (CV) of
the quantitative signal values between the intra-site replicates
was calculated using the generally detected subset of genes for
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each sample type HepG2 and MCF-7 at each laboratory. The
distribution of the replicate CV measures across the set of
detected genes is displayed in a series of box plots. The
different laboratories demonstrated similar replicate CV
median values of 1Æ962–3Æ234% for HepG2 and 1Æ869–
2Æ864% for MCF-7.
Fig 1. Unsupervised principal component analysis (PCA). A total of 204 experiments are included in the three-dimensional PCA and each sphere
represents the gene expression profile for a cell line or leukaemia sample. The signal used is DQN1. The first three principal components (PC) account
for 41Æ0% of variation of the data (PC1 = 18Æ1%, PC2 = 14Æ9%, PC3 = 8Æ0%). The analysis is based on all probe sets represented on the HG-U133
Plus 2.0 microarray without any filtering process (n = 54 613). Outliers are marked with arrows. (A) The same sample types are represented by the
same colour spheres. Distinct manufacturing batch numbers of the cell lines are given in Appendix SI. (B) Samples processed within the same centre
are represented by the same colour spheres.
Fig 2. Analysis of intra- and inter-laboratory reproducibility. (A) Box-and-whisker plots display, for each laboratory, the intra-laboratory squared
correlation coefficients (r2) of all probe sets represented on the HG-U133 Plus 2.0 microarray for the HepG2 cell line sample. The signal used is DS.
Each laboratory analysed six HepG2 samples using various amounts of starting total RNA: 1Æ0 lg, 1Æ5 lg, 3Æ0 lg, 5Æ0 lg (duplicate), or 8Æ0 lg,
respectively. Thus, all possible different pairwise comparisons were performed (Count). Mean r2 values (black arrow) and standard deviation (SD)
values are given for each of the series of comparisons for each laboratory. Outliers are represented as red boxes. Note: more comparisons were
performed in Centres 9 and 11 because multiple operators contributed microarray data (Appendix SII). (B) Repeatability of expression signal within
laboratories. The CV of the expression signal values between centre replicates of the same sample type was calculated for all generally detected genes
(left y-axis). The distributions of replicate CVs are presented in a series of eleven box-and-whisker plots: one for each of the two sample types HepG2
(left) or MCF-7 (right) at the eleven distinct laboratories. The median (line), interquartile range as well as the 10th and 90th percentile values are
indicated in each plot. Only genes that were generally detected were included in the box plots and CV calculations. The number of generally detected
genes was defined as being called present in at least one third of the samples, e.g., at least two out of the six replicates per centre. This number varied
by sample and laboratory and is noted as the line plot with the y-axis on the right. (C) Box-and-whisker plots display the inter-laboratory squared
correlation coefficients (r2) of all probe sets represented on the HG-U133 Plus 2.0 microarray for the HepG2 cell line sample. The signal used is DS.
Each centre analysed six HepG2 samples using various amounts of starting total RNA: 1Æ0 lg, 1Æ5 lg, 3Æ0 lg, 5Æ0 lg (duplicate), or 8Æ0 lg,
respectively. Here, microarray data from Centre 3 is compared with all other laboratories. Each inter-laboratory analysis with different pairwise
comparisons is represented by a single box plot (Count). Mean r2 values (black arrow) and standard deviation (SD) values are given for each series of
comparisons. Outliers are represented as red boxes. Note: more comparisons were performed in Centres 9 and 11 because multiple operators
contributed microarray data (Appendix SII). (D) Scatter plot analysis of inter-laboratory reproducibility. The graph shows 10 distinct scatter plot
analyses, each displaying a comparison between Centre 3 and the other laboratories for the 5Æ0 lg HepG2 sample run at the stage of proficiency
testing. The r2 value calculation is based on DS intensity signals from all probe sets on the HG-U133 Plus 2.0 microarray.
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Inter-laboratory reproducibility of gene expression
analyses
As an example of inter-laboratory reproducibility of gene
expression analyses, correlations between Centre 3 and all
other ten laboratories are given (Fig 2C and D). The degree of
correlation was only slightly different to the intra-laboratory
reproducibility (Fig 2C). The minimum and maximum mean
values were 0Æ959 and 0Æ985, respectively. This again demon-
strated a high inter-laboratory correlation of HepG2 gene
expression profiles and confirms the outstanding performance
of microarray analysis in the 11 centres. This high inter-
laboratory consistency can be also shown in pairwise scatter
plot analyses. The 5Æ0 lg HepG2 replicate analysis between
Centre 3 and other laboratories is shown as an example
(Fig 2D). A very tight distribution of gene expression data can
be observed along the diagonal line for every paired HepG2
sample. Additional analyses of inter-site correlations for
HepG2 subsets across all laboratories, along with hierarchical
cluster and principal component analyses, are given in
Appendix SI. Furthermore, the online section also contains
an analysis of the relative contribution of different sources of
both technical and biological variability in gene expression
measurements.
Discussion
Taken together, this study demonstrated that standardizing
experimental protocols for microarray analysis and performing
a thorough operator training resulted in excellent compara-
bility with respect to both data sets generated within a
participating laboratory and across 11 different laboratories in
three continents. This extends the observations of a recent
across-platform comparison study from the Toxicogenomics
Research Consortium (Bammler et al, 2005). In particular, and
also noted by Bammler et al (2005), the standardization of
RNA labelling protocols using common procedures was recog-
nized as an important contributor to signal intensity correla-
tions across different laboratories. Our study further shows
consistent results when compared with the intra-platform
precision demonstrated from three different centres in the
recent MicroArray Quality Consortia data (Shi et al, 2006).
In conclusion, this standardization effort represented the
prerequisite foundation of the first phase of the MILE study,
wherein 1889 patients have, thus far, been analysed by whole
genome expression microarrays (Haferlach et al, 2006). The
protocol devised for sample preparation takes only one
working day from cDNA synthesis to cocktail hybridization
and is easily applicable in a daily routine setting. The
standardization of gene expression profiling testing in this
way has the potential to offer identical objective diagnostic
results in any trained laboratory throughout the world. Thus,
microarrays are getting substantially closer to a routine
application of gene expression profiling for the diagnosis of
leukaemias in the clinical practice.
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